LIGACHEM BIOSCIENCES INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 70,000 KRW | +0.14% |
|
+5.26% | +7.69% |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 1,660,235 | 1,352,308 | 1,092,804 | 2,521,799 | - | - |
| Enterprise Value (EV) 2 | 1,609 | 1,184 | 1,093 | 2,003 | 2,055 | 2,104 |
| P/E ratio | -228 x | -57.5 x | -23.2 x | -67.4 x | -47.2 x | -42 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 33.6 x | 42.1 x | 32.7 x | 26.3 x | 34.5 x | 20 x |
| EV / Revenue | 32.6 x | 36.8 x | 32.7 x | 20.9 x | 28.1 x | 16.7 x |
| EV / EBITDA | -60.1 x | -48 x | -23.8 x | -57.2 x | -29.4 x | -36.3 x |
| EV / FCF | -91.3 x | -19.6 x | - | -64.6 x | -29.1 x | -42.1 x |
| FCF Yield | -1.1% | -5.1% | - | -1.55% | -3.43% | -2.38% |
| Price to Book | 14.8 x | 5.23 x | - | 4.5 x | 6.8 x | 5.63 x |
| Nbr of stocks (in thousands) | 23,684 | 24,235 | 25,503 | 36,026 | - | - |
| Reference price 3 | 70,100 | 55,800 | 42,850 | 70,000 | 70,000 | 70,000 |
| Announcement Date | 3/16/21 | 3/23/22 | 3/15/23 | - | - | - |
1KRW in Million2KRW in Billions3KRW
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | 49.39 | 32.16 | 33.41 | 96 | 73 | 126 |
| EBITDA 1 | -26.77 | -24.66 | -45.91 | -35 | -70 | -58 |
| EBIT 1 | -29.76 | -27.71 | -50.23 | -39 | -74 | -62 |
| Operating Margin | -60.25% | -86.16% | -150.34% | -40.62% | -101.37% | -49.21% |
| Earnings before Tax (EBT) 1 | -8.827 | -20.52 | -47.58 | -36 | -73 | -60 |
| Net income 1 | -6.986 | -23.39 | -44.95 | -36 | -70.5 | -60 |
| Net margin | -14.14% | -72.74% | -134.53% | -37.5% | -96.58% | -47.62% |
| EPS 2 | -307.0 | -970.0 | -1,845 | -1,039 | -1,484 | -1,666 |
| Free Cash Flow 3 | -17,633 | -60,358 | - | -31,000 | -70,500 | -50,000 |
| FCF margin | -35,698.54% | -187,696.99% | - | -32,291.67% | -96,575.34% | -39,682.54% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/16/21 | 3/23/22 | 3/15/23 | - | - | - |
1KRW in Billions2KRW3KRW in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 51 | 168 | - | 519 | 467 | 418 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 2 | -17,633 | -60,358 | - | -31,000 | -70,500 | -50,000 |
| ROE (net income / shareholders' equity) | -6.13% | -12.6% | - | -10.1% | -24.7% | -12.4% |
| ROA (Net income/ Total Assets) | -5.04% | -10.9% | - | 19% | -34.3% | - |
| Assets 1 | 138.7 | 214.6 | - | -189.5 | 205.5 | - |
| Book Value Per Share 3 | 4,734 | 10,678 | - | 15,565 | 10,288 | 12,442 |
| Cash Flow per Share 3 | - | - | - | 1,881 | -2,963 | - |
| Capex 1 | 2.74 | 18.3 | - | 2 | 3.5 | 2 |
| Capex / Sales | 5.55% | 56.94% | - | 2.08% | 4.79% | 1.59% |
| Announcement Date | 3/16/21 | 3/23/22 | 3/15/23 | - | - | - |
1KRW in Billions2KRW in Million3KRW
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +7.69% | 1.85B | |
| +8.33% | 115B | |
| +13.09% | 107B | |
| -12.85% | 22.31B | |
| -3.99% | 21.6B | |
| -6.71% | 18.23B | |
| -39.93% | 17.62B | |
| +6.25% | 14.26B | |
| +34.18% | 12.37B | |
| -28.78% | 8.28B |
- Stock Market
- Equities
- A141080 Stock
- Financials LigaChem Biosciences Inc.